首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Addition of capecitabine to maintenance endocrine therapy after induction therapy with bevacizumab plus paclitaxel in hormone receptor positive and HER2 negative metastatic breast cancer (KBCSG-TR1214)

【24h】

Addition of capecitabine to maintenance endocrine therapy after induction therapy with bevacizumab plus paclitaxel in hormone receptor positive and HER2 negative metastatic breast cancer (KBCSG-TR1214)

机译：在激素受体阳性和HER2阴性转移性乳腺癌中诱导治疗诱导治疗后的氯己酰疗法治疗内分泌疗法的加入内分泌治疗（KBCSG-TR1214）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共3页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献
中文文献
专利

1. Addition of capecitabine to maintenance endocrine therapy after induction therapy with bevacizumab plus paclitaxel in hormone receptor positive and HER2 negative metastatic breast cancer (KBCSG-TR1214) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：在激素受体阳性和HER2阴性转移性乳腺癌中诱导治疗诱导治疗后的氯己酰疗法治疗内分泌疗法的加入内分泌治疗（KBCSG-TR1214）
2. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer [J] . Xue-Lian Chen, Feng Du, Ruo-Xi Hong, Cancer Communications . 2016,第1期

机译：对于激素受体阳性和HER2阴性，转移性乳腺癌的患者，在一线基于卡培他滨的联合化疗后，激素治疗可能是比卡培他滨更好的维持治疗方法
3. A randomized, multicenter, phase II study evaluating the efficacy of interventional maintenance endocrine therapy with bevacizumab following fixed cycles of bevacizumab plus paclitaxel in advanced/metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 BOOSTER trial [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：随机，多中心，II期研究评估介入维持内分泌治疗与贝伐单抗后的贝伐单抗加紫杉醇在晚期/转移性ER阳性HER2阴性乳腺癌中的培养基中的疗效：JBCRG-M04增强试验
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. Treatment Interruption and Discontinuation of Hormone Therapy in Hormone Receptor-Positive Breast Cancer Patients [D] . Mao, Daqin . 2020

机译：激素受体阳性乳腺癌患者中的治疗中断与激素治疗中的中断和停止
6. Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy [O] . Alessandra Fabi, Michelangelo Russillo, Gianluigi Ferretti, 2012

机译：Her2-阴性激素受体阳性转移性乳腺癌患者维持贝伐单抗超过一线紫杉醇联合贝伐单抗的疗效：与激素疗法联合使用的疗效
7. Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy [O] . Alessandra Fabi, Michelangelo Russillo, Gianluigi Ferretti, 2012

机译：Her2-阴性激素受体阳性转移性乳腺癌患者维持贝伐单抗超过一线紫杉醇联合贝伐单抗的疗效：与激素疗法联合使用的疗效

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号